Fentanyl-Janssen

Quick links to important sections

Fentanyl-Janssen

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fentanyl-Janssen

Property Description
Active ingredient Fentanyl
Pharmacological class Opioid Analgesic
Origin Synthetic (Man-made)
Common use Management of severe pain
Key characteristic High potency and rapid action

What Type of Medicine is Fentanyl?

Fentanyl is classified as a highly potent synthetic opioid analgesic, defined by its chemical structure as a piperidine derivative, originally synthesized by Janssen Pharmaceutica in the 1950s. Its active ingredient is Fentanyl, which functions as a mu-opioid receptor agonist. This compound is clinically recognized for its exceptional potency, surpassing morphine by a factor of 50 to 100 times. The synthetic origin and high lipid solubility are key factors that contribute to its rapid entry into the central nervous system, distinguishing it from naturally derived opioids.

For What Purpose is Fentanyl Generally Used?

The general purpose of Fentanyl is to provide profound analgesia by modulating the body's perception of intense physical distress. It achieves this by activating specific opioid receptors in the central nervous system, effectively blocking the transmission of pain signals and inducing necessary sedation. This mechanism of action is widely adopted in medical practice for managing severe pain where rapid and comprehensive relief is essential, such as acting as an analgesic supplement during general anesthesia. Its citrate salt form is utilized as both an analgesic and an anesthetic adjunct.

What are the Common Pharmaceutical Forms of Fentanyl?

Fentanyl's versatility is reflected in the diverse range of delivery systems available, catering to different therapeutic needs. Common preparations include the solution for injection (used for rapid control in acute settings), the transdermal patch (designed for the sustained, long-term management of severe chronic pain), and various transmucosal preparations (such as lozenges or buccal films). The active ingredient, Fentanyl, is consistently utilized across these forms, integrated into distinct pharmaceutical bases to control its absorption rate into the systemic circulation.

Regulatory References

  1. National Institute on Drug Abuse (NIDA)

What side effects are possible with Fentanyl-Janssen?

Possible Side Effects and Safety Information: Fentanyl-Janssen

Fentanyl's official safety profile, documented by government regulatory bodies, classifies adverse reactions by frequency and physiological system. This framework defines the medicine's risk characteristics without providing clinical advice.

Category Description
Key Adverse Reaction Categories Gastrointestinal, Nervous System, Psychiatric, and Respiratory disorders are the main systems affected by documented adverse reactions.
Frequency Classification Adverse effects are formally categorized as Very Common (ge 1/10), Common (ge 1/100 to < 1/10), Uncommon (ge 1/1,000 to < 1/100), and Rare (ge 1/10,000 to < 1/1,000).
System-Organ Classes Involved Gastrointestinal Disorders (Nausea, Vomiting, Constipation), Nervous System Disorders (Somnolence, Dizziness, Headache), and Psychiatric Disorders (Confusion, Anxiety).

Serious Adverse Reactions (Label-Documented) The most clinically significant risks explicitly highlighted in regulatory labels include life-threatening Respiratory Depression, Circulatory Depression, and Respiratory Arrest. Other serious reactions noted are Serotonin Syndrome (when used with certain other medications), Severe Hypersensitivity reactions, and Adrenal Insufficiency.

Safety Considerations and Constraints

The medicine carries a regulatory warning regarding the risks of Misuse, Abuse, and Addiction. Its use is constrained by the severe risk of profound sedation, respiratory depression, and death when administered concurrently with CNS depressants (including alcohol). Regulatory documents note specific caution for use in older adults and patients with renal or hepatic impairment due to potential changes in drug clearance. Furthermore, chronic exposure is associated with the development of Tolerance and Physical Dependence, and the risk of Neonatal Opioid Withdrawal Syndrome if used during pregnancy.

Regulatory Safety Summary

  • Commonly observed effects primarily involve the gastrointestinal and nervous systems, including Nausea, Constipation, Somnolence, and Dizziness.
  • Serious and life-threatening risks are centered on profound respiratory and circulatory depression, which is explicitly highlighted in the official warnings.
  • Long-term use is associated with the official documentation of Tolerance, Physical Dependence, and the risks of misuse, abuse, and addiction.

The official safety information structures the understanding of risk by clearly categorizing adverse events by frequency and system, allowing for recognition of both expected and severe outcomes. The documented safety profile establishes that the inherent high potency and opioid classification necessitate explicit warnings regarding life-threatening respiratory depression and the potential for dependence, which are central to the drug's regulatory constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that the major hazard of Fentanyl overdose is life-threatening respiratory depression, which can be fatal. Signs of overdose are an intensification of the drug's effects and include severe central nervous system and respiratory compromise.

Overdose can occur following accidental exposure, especially in children or individuals not tolerant to opioids, or due to administration errors, and requires immediate emergency medical attention.


Documented Overdose Manifestations

Physiological System Signs and Symptoms (as per regulatory documents)
Respiratory Slowed or shallow breathing, long pauses between breaths, difficulty breathing, apnea.
Central Nervous System Excessive drowsiness, stupor, coma, decreased awareness, loss of consciousness.
Cardiovascular Slowed heart rate (bradycardia), severe low blood pressure (hypotension).
Other Cold, clammy skin; pupillary constriction (pinpoint pupils).

Emergency Actions and When to Seek Help

Immediate medical help is required if any of the above serious signs are suspected or observed. The primary emergency response is focused on restoring a patent airway and providing controlled or assisted ventilation, as instructed in official labeling.

In the event of a suspected overdose, call for emergency medical assistance right away. Medical staff may administer an opioid antagonist, such as naloxone, to attempt to reverse the opioid effects. Due to the duration of Fentanyl's effects, repeat administration of the antagonist may be necessary.

Therapeutic Uses of Fentanyl-Janssen

What Fentanyl-Janssen Treats: Main Uses and Benefits

The medication is commonly used for managing pain of severe intensity where immediate and profound analgesic support is appropriate. It is generally applied in clinical contexts where other symptomatic management may not be appropriate for the level of distress experienced. It is indicated for the treatment of severe pain, such as pain following surgical procedures or other types of severe chronic pain that do not respond sufficiently to other pain medications.

The primary therapeutic applications play a role in managing severe, persistent pain in opioid-tolerant patients, such as advanced cancer-related pain; supporting intense acute pain in postoperative and critical settings; and addressing sudden, temporary paroxysmal pain episodes (breakthrough pain).

“The primary benefit of its use is offering symptomatic relief that assists with maintaining functional stability and easing the impact of overwhelming acute manifestations.”

Control of Severe Chronic Pain in Opioid-Tolerant Patients

This domain is relevant for managing severe, persistent pain, most often associated with conditions like advanced cancer, in patients who are already tolerant to opioid therapy. The medication is commonly used in situations requiring long-term, stable, and continuous supportive relief to maintain patient comfort. Its key therapeutic benefit is contributing to easing the overall symptom load, supporting patients during difficult, high-intensity pain.

Management of Acute and Postoperative Distress

Fentanyl is also applied in clinical settings for the immediate control of intense acute pain, such as the severe physical discomfort experienced in the perioperative period or as an anesthetic adjunct. It is generally relevant when short-term symptomatic assistance is needed. The primary benefit is offering symptomatic relief that assists with maintaining functional stability and easing the impact of acute manifestations.


Quick Fact: Relief for Severe, Unrelenting Pain

Regulatory References

  1. National Institute on Drug Abuse (NIDA) at NIH

Eligibility and Restrictions for Use

Fentanyl-Janssen (a form of fentanyl) is a strong opioid analgesic intended for the management of severe, chronic pain that requires continuous, around-the-clock opioid administration for an extended time, and cannot be managed by other means. It is generally reserved for patients who have already demonstrated opioid tolerance—meaning they have been regularly taking another potent opioid for a week or longer.


Contraindications and Patient Safety

Fentanyl-Janssen is not suitable for individuals who are not opioid-tolerant, or for treating non-chronic pain conditions such as mild pain, acute pain, or postoperative pain (including after outpatient or day surgeries).

It is also contraindicated in patients with the following conditions due to the risk of serious or fatal respiratory depression:

  • Acute or severe bronchial asthma or other significant breathing difficulties.
  • Respiratory depression (serious breathing problem).
  • Known or suspected gastrointestinal obstruction, such as paralytic ileus.
  • Known hypersensitivity or allergy to fentanyl or any component of the formulation.

Caution is required for patients with pre-existing conditions like severe kidney or liver impairment, head injuries, increased intracranial pressure, or a history of drug dependence.

What should I know about interactions with other medicines?

The official interaction profile for Fentanyl is structured around pharmacokinetic effects and pharmacodynamic considerations, defining mandatory constraints for use.

Pharmacokinetic Interactions

Co-administration with strong or moderate CYP3A4 inhibitors (such as certain antivirals or antifungals) can significantly increase fentanyl plasma concentrations due to reduced drug clearance. The discontinuation of a CYP3A4 inducer may also result in increased drug exposure, while co-administration with inducers may reduce concentrations. Ingestion of Grapefruit Juice may pose a similar risk due to its CYP3A4 inhibitory properties.

Pharmacodynamic Interactions and Prohibitions

Fentanyl is formally contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI. The concurrent use of Central Nervous System (CNS) depressants, including Benzodiazepines, other sedative hypnotics, and Alcohol, is associated with an additive CNS depressant effect, risking profound sedation and respiratory depression. Use with certain Serotonergic Drugs may result in Serotonin Syndrome. The label advises avoiding co-use with mixed agonist/antagonist opioids, as this may reduce the analgesic effect. A non-drug constraint is the restriction on applying external heat to the transdermal patch site, which can increase drug absorption, and transmucosal forms require at least 4 hours between doses.

Mechanism of Action

Fentanyl is an agonist that selectively binds to the mu-opioid receptor ( MOR), a G-protein coupled receptor (GPCR). This binding occurs primarily within the central nervous system, including the spinal cord and brain, at sites involved in nociception.

Upon binding, Fentanyl stabilizes the MOR in its active conformation, which initiates the dissociation of the inhibitory G i/ o protein complex. The activated Gbetagamma subunits inhibit voltage-gated Ca^2+ channels, reducing calcium influx into the neuron. Concurrently, the activated Galpha subunits stimulate K^+ efflux by activating GIRK channels, leading to hyperpolarization of the neuronal membrane.

These coupled cellular events decrease the excitability of the neuron. The resulting reduction in action potential propagation leads to a presynaptic decrease in the release of various excitatory neurotransmitters, including Substance P and glutamate, particularly at the primary afferent terminals in the dorsal horn. This modulation alters the transmission of nociceptive signals.

Dosage and Administration Information

How to Use Fentanyl-Janssen

Fentanyl-Janssen is a medicine administered via different routes, including transdermal (patch) and oromucosal (buccal/sublingual forms), based on the specific formulation. Following the prescribed administration instructions is mandatory to ensure correct dosing and absorption.

Administration Guidelines

Administration Aspect Transdermal Patch Instructions Oromucosal/Sublingual Instructions
Route & Frequency Apply one patch every 72 hours (3 days). Always remove the old patch before applying a new one. Used as needed for breakthrough episodes; limit to two doses per episode (the second dose used if the first is insufficient). Wait at least 4 hours before treating a subsequent episode.
Preparation Select a dry, intact, flat area of skin (e.g., chest or upper arm). Clean the site with clear water only; dry thoroughly. Do not use soap, oils, or alcohol and do not cut the patch. Do not split, crush, or chew the tablet or lozenge. Patients with dry mouth may be instructed to moisten the buccal cavity with water prior to administration.
Placement & Duration Press firmly on the skin for at least 30 seconds to ensure full adherence. Avoid exposing the site to external heat (e.g., heating pads, sauna). Place the unit between the cheek and gum or under the tongue. Allow it to dissolve completely without sucking, chewing, or swallowing the entire unit (dissolution can take 15–30 minutes).
Missed Dose Apply a new patch as soon as remembered and resume the 72-hour cycle from that time. No specific missed-dose instruction, as it is used on an as-needed basis for pain episodes.
Disposal Immediately fold the used patch so the adhesive sides stick together, and flush down the toilet or dispose of as instructed for controlled substances.

These guidelines define the standardized procedure for using the medicine. Dosing is highly individualized and must be determined and managed by a healthcare provider.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Research Scope

Studies examined the potential for the drug to affect the frequency and severity of headaches in chronic migraine patients. The trials reported findings aligned with their primary endpoints regarding the drug’s use. The majority of research focused on adult patients diagnosed with chronic migraine, and the drug’s profile remains under study in adolescent populations.

In some studies, participants reported changes in symptoms over a short timeframe.

Key Clinical Trials

The 6-Month Quality-of-Life Study (Phase III)

This randomized, placebo-controlled trial included 500 participants across 10 centers. The study design included evaluating the drug's administration at the initial presence of headache symptoms.

A major clinical trial reported changes in scores on quality of life assessments and in the count of headache days over a six-month period. The study’s primary endpoint was the change in monthly headache days from baseline, and secondary endpoints included measures of functional ability.

Combination Therapy Research

The clinical strategy for some trials included combining this drug with other pain management strategies. Other studies were conducted to evaluate the drug alongside currently available treatments.

Some research findings explored the relationship between the combination and patient function. The clinical profile of this area is a subject of ongoing research.

Special Populations and Research Gaps

Research has explored the drug's profile in individuals with mild or severe liver impairment; patient suitability for treatment remains a clinical decision. Studies have not yet confirmed the clinical profile of the drug for pregnant or breastfeeding individuals.

All decisions regarding suitability for treatment must be made in consultation with a qualified healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Fentanyl-Janssen (FAQ)

Q: Does Fentanyl-Janssen work the same way as natural opioids?

Fentanyl is classified as a synthetic opioid, meaning it is man-made. It works similarly to naturally derived opioids by targeting and activating the mu-opioid receptors in the central nervous system. This action is associated with the medicine's role in pain relief.


Q: What is the general expected duration of action for Fentanyl-Janssen?

The duration of the medicine’s effect varies based on the formulation. Transdermal patches are designed to provide continuous delivery of the medicine over approximately 72 hours. Transmucosal forms are generally used with a minimum interval of four hours between administrations, as described in official labeling.


Q: Are there differences in how quickly various forms of Fentanyl-Janssen start working?

Yes, different formulations are designed to work at different speeds. Transmucosal forms are intended for rapid action to manage sudden pain episodes. Conversely, the transdermal patch is formulated for the slow, sustained release of the medicine over a period of days to treat chronic pain.


Q: Are there any known long-term health effects examined in studies on Fentanyl-Janssen?

Clinical trials evaluate the medicine's profile over extended periods. For instance, studies such as the 6-month Quality-of-Life study have assessed long-term metrics. These included changes in the frequency of headache days and measurements of functional ability in patients with chronic pain.


Q: What happens if Fentanyl-Janssen is stopped too quickly after long-term use?

Official information indicates that chronic use of this medicine is associated with the development of physical dependence. Due to this risk, stopping the medicine abruptly can result in a withdrawal syndrome, which involves a range of physical and psychological symptoms. The process of discontinuation should always be managed and supervised by a healthcare provider.


Q: Can Fentanyl-Janssen interact with herbal supplements or over-the-counter medicines?

Official information highlights that certain non-drug substances can interact by affecting an enzyme called CYP3A4. For example, consuming Grapefruit Juice can reduce the clearance of the medicine, leading to increased concentration in the body. It is generally described as important to inform a healthcare provider about all medicines, supplements, and foods being consumed.


Q: Is Fentanyl-Janssen typically used to treat severe chronic pain or only breakthrough cancer pain?

The use is specific to the formulation. The transdermal patch is indicated for the continuous management of persistent, severe chronic pain in opioid-tolerant patients. However, transmucosal forms, such as the lozenge or buccal tablet, are specifically indicated for the management of breakthrough cancer pain.


Q: What is the difference between prescription Fentanyl-Janssen and illicitly manufactured fentanyl?

Prescription Fentanyl-Janssen is a synthetic opioid manufactured under strict regulation for legitimate medical use, ensuring consistent quality and dosage. Illicitly manufactured fentanyl (IMF) is unregulated, often contains unpredictable and inconsistent composition, and is the subject of public health warnings.


Q: Is Fentanyl-Janssen a narcotic or an opioid according to the official classification?

Fentanyl is formally classified as a potent opioid analgesic based on its mechanism of action. Due to its potential for dependence and abuse, the medicine is also regulated as a Schedule II controlled substance. This controlled category is sometimes informally referred to by the public as a narcotic.


Q: Why is Fentanyl-Janssen considered so much more potent than morphine?

The extreme potency of Fentanyl, which is described as 50 to 100 times greater than morphine, is related to its chemical properties. Fentanyl has high lipid solubility, which allows it to pass quickly into the central nervous system. It also binds strongly to the mu-opioid receptor, resulting in a pronounced analgesic effect.


Q: What is the general approach to discontinuing Fentanyl-Janssen after long-term use?

Due to the risk of physical dependence and potential withdrawal symptoms, the medicine should never be stopped suddenly. Official guidance describes that the dosage is gradually reduced, or tapered, over time. This process must be managed and supervised by a healthcare provider.


Q: Can the effectiveness of Fentanyl-Janssen be reduced by certain foods or beverages?

Official product information notes that co-administering the medicine with certain substances, particularly those that increase the activity of the CYP3A4 enzyme (CYP3A4 inducers), can reduce the concentration of fentanyl in the body. This reduction could potentially lead to a decrease in its expected pain-relieving effect.


Q: How quickly does the pain relief from Fentanyl-Janssen typically begin?

The time required to achieve pain relief varies by formulation. Transmucosal forms are designed for quick relief and often begin working within 5 to 15 minutes. In contrast, the transdermal patch is intended for continuous pain control and typically requires 12 to 24 hours to reach adequate pain-relieving concentrations in the bloodstream.


Q: Why do people sometimes need other pain medicine until the Fentanyl-Janssen patch starts working?

The transdermal patch is designed to release the medicine slowly and continuously. Because it takes 12 to 24 hours to build up effective concentrations of fentanyl in the blood, patients may be prescribed supplemental immediate-release opioids. This is intended to provide supplemental pain management during the initial period before the patch reaches its full effect.


Q: What should be done to manage typical side effects like dry mouth or dizziness from Fentanyl-Janssen?

If a patient experiences dry mouth while using transmucosal forms, official instructions may advise moistening the mouth with water before administration. For side effects like dizziness, official safety information advises caution regarding movements and suggests reporting persistent effects to a healthcare provider.


Q: Does Fentanyl-Janssen have a potential to cause hyperalgesia (increased pain sensitivity)?

Yes, official FDA labeling documents note the risk of a condition known as Opioid-Induced Hyperalgesia (OIH). This is described as a paradoxical increase in pain or sensitivity to pain that can sometimes occur during the use of opioids.


Q: Is it true that Fentanyl-Janssen is primarily prescribed by specialized pain physicians?

Regulatory requirements dictate that the prescriber must be knowledgeable in the use of potent opioids for chronic pain. Furthermore, certain high-risk formulations may require the prescriber to be specifically enrolled in a specialized FDA Risk Evaluation and Mitigation Strategy (REMS) program.


Q: What is the purpose of the Risk Evaluation and Mitigation Strategy (REMS) program often associated with this type of medicine?

The REMS program is a safety strategy mandated by the FDA to manage the known or potential serious risks of a medication. For Fentanyl, this program is centered on minimizing the severe risks of abuse, misuse, addiction, and accidental exposure.


Q: What does it mean if a medicine like Fentanyl-Janssen is a Schedule II controlled substance?

Classification as a Schedule II controlled substance by the DEA means the drug has a high potential for abuse and may lead to severe psychological or physical dependence. While it is accepted for legitimate medical use, it requires strict legal controls.


Q: Can a Fentanyl-Janssen patch accidentally stick to someone else and cause harm?

Yes, official warnings emphasize the risk of accidental secondary exposure. This is a critical safety constraint, as the transfer of a used or unused patch to another person, especially a child, can lead to serious adverse events including a fatal overdose.


Q: What are the official guidelines about activities like driving or operating machinery while using Fentanyl-Janssen?

Official guidelines warn that Fentanyl can cause sedation, dizziness, and impaired mental and physical abilities. Patients must use extreme caution, or avoid activities such as driving or operating potentially hazardous machinery, until the medicine's effects are known.


Q: Is a rash at the patch application site a common occurrence with Fentanyl-Janssen?

Reports of skin reactions at the application site, such as redness, rash, or itching, have been noted in the official adverse reactions documentation. Official administration instructions emphasize applying the transdermal patch only to intact, non-irritated skin.


Q: Are there specific dental hygiene considerations when using Fentanyl-Janssen lozenges?

Some formulations of the lozenge may contain sugar. For this reason, official patient information often advises maintaining good dental hygiene while using these transmucosal products to help mitigate potential dental issues.


Q: How do I know if Fentanyl-Janssen is the correct product prescribed to me?

Patients are advised to check the medicine's name, strength, and dosage form (e.g., patch, lozenge, tablet) against the description provided by their healthcare professional. It is recommended in patient counseling information to verify that these details match the information printed on the pharmacy label before use.


Q: Are there different brand names for Fentanyl that are made by Janssen?

Janssen Pharmaceutica, or its associated companies, has been involved in the development and marketing of different brand names for Fentanyl. One notable example of a branded fentanyl product is the transdermal system known as DURAGESIC.


Q: Are there different strengths of Fentanyl-Janssen available?

Yes, Fentanyl is produced in a variety of strengths across its different dosage forms. For instance, the transdermal patch is typically available in a range of strengths, often measured from 12 micrograms per hour up to 100 micrograms per hour.

How should Fentanyl-Janssen be stored and disposed of?

How to Store and Dispose of Fentanyl

Official regulatory guidelines mandate strict storage and disposal procedures for Fentanyl products due to their potency and the high risk of fatal accidental exposure.


Storage Requirements

Fentanyl must be stored in a safe, secure place out of the sight and reach of children and pets, often recommending a locked container. The medication must remain in its original sealed container at controlled room temperature.

Handling Constraint: Patients must avoid exposing the medication or the application site (for patches) to external heat sources, as this can dangerously increase drug release.


Disposal Instructions

Disposal must occur immediately upon removal or when the medication is no longer needed. The preferred method is using a drug take-back program or authorized collection site.

If a take-back option is unavailable, certain high-risk forms, such as the transdermal patch, must be disposed of by folding the adhesive sides together and immediately flushing it down the toilet to prevent accidental ingestion or diversion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fentanyl-Janssen found in:

A-Z Index: